Circle Of Life: Raptor Buys Quinsair After Its Return To Original Developer
This article was originally published in Scrip
Executive Summary
Quinsair (inhaled levofloxacin) – originally known as Aeroquin – took a circuitous route to its new home at Raptor Pharmaceuticals, which will pay Tripex Pharmaceuticals $68.4m up front and up to $350m in milestone fees plus a small royalty for the cystic fibrosis (CF) drug.
You may also be interested in...
Finance Watch: Investment In Novel Antibacterials Gets A New Boost With Qpex Launch
Repeat antibiotic entrepreneurs raised $33m to launch Qpex with assets from The Medicines Co. Also, Taiho increases VC fund to $300m and TP Therapeutics raises $80m.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.